On the other hand, by expressing the AMAP1 SH3 domain, we have shown that the AMAP1 SH3 domain is predominantly used for the binding to paxillin, but not to cortactin, in malignant breast cancer cells ((37); Figure 4). This evidence concerns the gene CTTN and breast carcinoma.